Literature DB >> 18315495

Thioredoxin in vascular biology: role in hypertension.

Talin Ebrahimian1, Rhian M Touyz.   

Abstract

The thioredoxin (TRX) system consists of TRX, TRX reductase, and NAD(P)H, and is able to reduce reactive oxygen species (ROS) through interactions with the redox-active center of TRX, which in turn can be reduced by TRX reductase in the presence of NAD(P)H. Among the TRX superfamily is peroxiredoxin (PRX), a family of non-heme peroxidases that catalyzes the reduction of hydroperoxides into water and alcohol. The TRX system is active in the vessel wall and functions either as an important endogenous antioxidant or interacts directly with signaling molecules to influence cell growth, apoptosis, and inflammation. Recent evidence implicates TRX in cardiovascular disease associated with oxidative stress, such as cardiac failure, arrhythmia, ischemia reperfusion injury, and hypertension. Thioredoxin activity is influenced by many mechanisms, including transcription, protein-protein interaction, and post-translational modification. Regulation of TRX in hypertensive models seems to be related to oxidative stress and is tissue- and cell-specific. Depending on the models of hypertension, TRX system could be upregulated or downregulated. The present review focuses on the role of TRX in vascular biology, describing its redox activities and biological properties in the media and endothelium of the vessel wall. In addition, the pathopysiological role of TRX in hypertension and other cardiovascular diseases is addressed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18315495     DOI: 10.1089/ars.2007.1985

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  22 in total

Review 1.  Oxidant Mechanisms in Renal Injury and Disease.

Authors:  Brian B Ratliff; Wasan Abdulmahdi; Rahul Pawar; Michael S Wolin
Journal:  Antioxid Redox Signal       Date:  2016-04-26       Impact factor: 8.401

Review 2.  The COP9 signalosome and vascular function: intriguing possibilities?

Authors:  Douglas S Martin; Xuejun Wang
Journal:  Am J Cardiovasc Dis       Date:  2015-03-20

3.  Levels of thioredoxin are related to the severity of obstructive sleep apnea: based on oxidative stress concept.

Authors:  Qian Guo; Yan Wang; Qing Yun Li; Min Li; Huan Ying Wan
Journal:  Sleep Breath       Date:  2012-03-22       Impact factor: 2.816

4.  Hypoxia inhibits expression and function of mitochondrial thioredoxin 2 to promote pulmonary hypertension.

Authors:  Sherry E Adesina; Brandy E Wade; Kaiser M Bijli; Bum-Yong Kang; Clintoria R Williams; Jing Ma; Young-Mi Go; C Michael Hart; Roy L Sutliff
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-01-27       Impact factor: 5.464

Review 5.  Oxidative stress and hypertension: current concepts.

Authors:  Ana M Briones; Rhian M Touyz
Journal:  Curr Hypertens Rep       Date:  2010-04       Impact factor: 5.369

Review 6.  The role of the thioredoxin/thioredoxin reductase system in the metabolic syndrome: towards a possible prognostic marker?

Authors:  Alexey A Tinkov; Geir Bjørklund; Anatoly V Skalny; Arne Holmgren; Margarita G Skalnaya; Salvatore Chirumbolo; Jan Aaseth
Journal:  Cell Mol Life Sci       Date:  2018-01-11       Impact factor: 9.261

Review 7.  The thioredoxin system in neonatal lung disease.

Authors:  Trent E Tipple
Journal:  Antioxid Redox Signal       Date:  2014-03-13       Impact factor: 8.401

Review 8.  Potential therapeutic benefits of strategies directed to mitochondria.

Authors:  Amadou K S Camara; Edward J Lesnefsky; David F Stowe
Journal:  Antioxid Redox Signal       Date:  2010-08-01       Impact factor: 8.401

Review 9.  Oxidative stress in hypertension: role of the kidney.

Authors:  Magali Araujo; Christopher S Wilcox
Journal:  Antioxid Redox Signal       Date:  2013-04-30       Impact factor: 8.401

10.  Modulatory Effects of Mild Carbon Monoxide Exposure in the Developing Mouse Cochlea.

Authors:  Ivan A Lopez; Dora Acuna; John Edmond
Journal:  Neurochem Res       Date:  2016-03-19       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.